Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486223 · ClinicalTrials.gov registry record · Phase 2
Soluble Epoxide Hydrolase Inhibition and Insulin Resistance
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03486223 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 16 participants.
The verdict
NCT03486223, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to test how soluble epoxide hydrolase (sEH) inhibition with GSK2256294 affects tissue sEH activity and insulin sensitivity.
Interventions
- DRUG Placebo oral capsule
- DRUG GSK2256294
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-05-17 |
| Est. Completion | 2021-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486223
The ClinicalTrials.gov registry entry for NCT03486223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03486223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486223 about?
NCT03486223 is a clinical study titled "Soluble Epoxide Hydrolase Inhibition and Insulin Resistance". The purpose of this study is to test how soluble epoxide hydrolase (sEH) inhibition with GSK2256294 affects tissue sEH activity and insulin sensitivity.
What is the current status of trial NCT03486223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-05-17. Estimated completion is 2021-11-18.
What interventions are being tested in trial NCT03486223?
The interventions under investigation include: Placebo oral capsule (DRUG), GSK2256294 (DRUG).
Who is sponsoring clinical trial NCT03486223?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.